Characteristics of Pneumothorax Associated With Transthoracic Percutaneous Lung Biopsy in Standard of Care

NCT ID: NCT05259293

Last Updated: 2024-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

243 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-09

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The number of lung biopsies has increased steadily in recent years. Pneumothorax is the most common complication of a lung biopsy and can occur during the procedure, immediately after the procedure or within a few hours (delayed pneumothorax). The incidence of pneumothorax in the literature is very different from one study to another: it has been reported to be from 9 to 54% in patients undergoing percutaneous transthoracic needle biopsy. This difference of incidence could be explained by the absence of consensus for the definition of an iatrogenic pneumothorax.

The characteristics of pneumothorax and the management of patients with iatrogenic pneumothorax will be evaluated in different centres in a retrospective manner. This study will contribute to refining the criteria for defining pneumothorax occurring during lung biopsy and will provide a better understanding of the condition and its management.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumothorax Iatrogenic Postprocedural

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention - retrospective study

This is a retrospective study. No intervention.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years old and more at the time of the biopsy procedure in year 2020
* Having had a pneumothorax following their transthoracic percutaneous lung biopsy in year 2020

Exclusion Criteria

* Objection to the use of the data (French sites only)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role collaborator

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Julien BEHR, MD

Role: PRINCIPAL_INVESTIGATOR

CHU de Besançon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Besançon

Besançon, , France

Site Status

Institut Bergonié

Bordeaux, , France

Site Status

CHU de Tours

Tours, , France

Site Status

Institut Gustave Roussy

Villejuif, , France

Site Status

Saint James Hospital

Dublin, , Ireland

Site Status

Oxford University Hospitals

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Ireland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021/625

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CT-guided Lung Biopsy Risk Optimization Method
NCT06340178 NOT_YET_RECRUITING NA